...
首页> 外文期刊>Trends in pharmacological sciences >Na(V)1.7 as a Pharmacogenomic Target for Pain: Moving Toward Precision Medicine
【24h】

Na(V)1.7 as a Pharmacogenomic Target for Pain: Moving Toward Precision Medicine

机译:Na(v)1.7作为疼痛的药物替代品靶标:走向精密药物

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic pain is a global unmet medical need. Most existing treatments are only partially effective or have side effects that limit their use. Rapid progress in elucidating the contribution of specific genes, including those that encode peripheral voltage-gated sodium channels, to the pathobiology of chronic pain suggests that it may be possible to advance pain pharmacotherapy. Focusing on voltage-gated sodium channel Na(V)1.7 as an example, this article reviews recent progress in developing patient-specific induced pluripotent stem cells (iPSCs) and their differentiation into sensory neurons, together with advances in structural modeling, that have provided a basis for first-in-human translational studies. These new approaches will hopefully transform the treatment of pain from trial-and-error toward genomically guided, precision pharmacotherapy.
机译:慢性疼痛是全球未满足的医疗需求。 大多数现有的治疗仅部分有效或有限制其使用的副作用。 阐明特定基因的贡献的快速进展,包括编码外周电压门控钠通道的贡献,慢性疼痛的病理学表明,可以推进疼痛药物治疗。 专注于电压门控钠通道Na(v)1.7作为一个例子,本文综述了最近在制育患者特异性诱导的多能干细胞(IPSC)和它们分化为感觉神经元的进展,以及所提供的结构建模的进展 先进名翻译研究的基础。 这些新方法希望将疼痛的治疗从试验和误差转向基因组导向,精密药物疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号